BACKGROUND: Although reduction in the JAK2(V617F) allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy. DESIGN AND METHODS: We compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFNα-2b: 28, Peg-rIFNα-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria. RESULTS: Of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups. CONCLUSIONS: Generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera.
BACKGROUND: Although reduction in the JAK2(V617F) allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy. DESIGN AND METHODS: We compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFNα-2b: 28, Peg-rIFNα-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria. RESULTS: Of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups. CONCLUSIONS: Generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera.
Authors: Amy V Jones; Richard T Silver; Katherine Waghorn; Claire Curtis; Sebastian Kreil; Katerina Zoi; Andreas Hochhaus; David Oscier; Georgia Metzgeroth; Eva Lengfelder; Andreas Reiter; Andrew J Chase; Nicholas C P Cross Journal: Blood Date: 2005-12-13 Impact factor: 22.113
Authors: Shireen Sirhan; Terra L Lasho; Curtis A Hanson; Ruben A Mesa; Animesh Pardanani; Ayalew Tefferi Journal: Am J Hematol Date: 2008-05 Impact factor: 10.047
Authors: Naseema Gangat; Jacob Strand; Terra L Lasho; Christy M Finke; Ryan A Knudson; Animesh Pardanani; Chin-Yang Li; Rhett P Ketterling; Ayalew Tefferi Journal: Eur J Haematol Date: 2007-12-07 Impact factor: 2.997
Authors: Emil T Kuriakose; Stefani Gjoni; Y Lynn Wang; Ruth Baumann; Amy V Jones; Nicholas C P Cross; Richard T Silver Journal: Haematologica Date: 2013-11 Impact factor: 9.941
Authors: Nicole C C Them; Klaudia Bagienski; Tiina Berg; Bettina Gisslinger; Martin Schalling; Doris Chen; Veronika Buxhofer-Ausch; Josef Thaler; Ernst Schloegl; Guenther A Gastl; Dominik Wolf; Karin Strecker; Alexander Egle; Thomas Melchardt; Sonja Burgstaller; Ella Willenbacher; Oleh Zagrijtschuk; Christoph Klade; Richard Greil; Heinz Gisslinger; Robert Kralovics Journal: Am J Hematol Date: 2015-03-02 Impact factor: 10.047